US21867A1051 - Common Stock

**CLB** gets a fundamental rating of **4** out of 10. The analysis compared the fundamentals against 61 industry peers in the **Energy Equipment & Services** industry. **CLB** has only an average score on both its financial health and profitability. **CLB** has a expensive valuation and it also scores bad on growth.

In the past year **CLB** had a positive cash flow from operations.

In multiple years **CLB** reported negative net income over the last 5 years.

Of the past 5 years **CLB** 4 years had a positive operating cash flow.

The **Average Return On Invested Capital** over the past 3 years for **CLB** is in line with the industry average of **8.37%**.

The last **Return On Invested Capital** (**8.97%**) for **CLB** is above the 3 year average (**7.69%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 6.26% | ||

ROE | 16.32% | ||

ROIC | 8.97% |

ROA(3y)4.34%

ROA(5y)1.8%

ROE(3y)13.16%

ROE(5y)-7.94%

ROIC(3y)7.69%

ROIC(5y)8.82%

In the last couple of years the **Profit Margin** of **CLB** has declined.

The **Operating Margin** of **CLB** (**11.27%**) is better than **62.30%** of its industry peers.

In the last couple of years the **Operating Margin** of **CLB** has declined.

In the last couple of years the **Gross Margin** of **CLB** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 11.27% | ||

PM (TTM) | 7.2% | ||

GM | 21.54% |

OM growth 3Y-2.8%

OM growth 5Y-8.16%

PM growth 3YN/A

PM growth 5Y-8.71%

GM growth 3Y-2.28%

GM growth 5Y-5.83%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **CLB** is still creating some value.

There is no outstanding debt for **CLB**. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

An Altman-Z score of **3.37** indicates that **CLB** is not in any danger for bankruptcy at the moment.

A Debt/Equity ratio of **0.73** indicates that **CLB** is somewhat dependend on debt financing.

The **Debt to Equity ratio** of **CLB** (**0.73**) is worse than **72.13%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.73 | ||

Debt/FCF | 11.48 | ||

Altman-Z | 3.37 |

ROIC/WACC1.07

WACC8.4%

The **Quick ratio** of **CLB** (**1.72**) is better than **72.13%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.53 | ||

Quick Ratio | 1.72 |

The **Earnings Per Share** has been growing slightly by **3.66%** over the past year.

EPS 1Y (TTM)3.66%

EPS 3Y4.92%

EPS 5Y-14.36%

EPS Q2Q%13.64%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%7.22%

Based on estimates for the next years, **CLB** will show a small growth in **Revenue**. The Revenue will grow by **3.70%** on average per year.

EPS Next Y20.71%

EPS Next 2Y16.17%

EPS Next 3Y17.29%

EPS Next 5Y14.82%

Revenue Next Year5.11%

Revenue Next 2Y3.86%

Revenue Next 3Y4.27%

Revenue Next 5Y3.7%

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The rest of the industry has a similar **Price/Earnings** ratio as **CLB**.

The average S&P500 **Price/Earnings** ratio is at **29.17**. **CLB** is around the same levels.

Based on the **Price/Forward Earnings** ratio of **20.97**, the valuation of **CLB** can be described as rather expensive.

Based on the **Price/Forward Earnings** ratio, **CLB** is valued a bit more expensive than the industry average as 72.13% of the companies are valued more cheaply.

When comparing the **Price/Forward Earnings** ratio of **CLB** to the average of the S&P500 Index (**23.71**), we can say **CLB** is valued inline with the index average.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 24.42 | ||

Fwd PE | 20.97 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **CLB** indicates a rather expensive valuation: **CLB** more expensive than 88.52% of the companies listed in the same industry.

67.21% of the companies in the same industry are cheaper than **CLB**, based on the **Price/Free Cash Flow** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 68.59 | ||

EV/EBITDA | 15.33 |

The **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

A more expensive valuation may be justified as **CLB**'s earnings are expected to grow with **17.29%** in the coming years.

PEG (NY)1.18

PEG (5Y)N/A

EPS Next 2Y16.17%

EPS Next 3Y17.29%

With a yearly dividend of 0.19%, **CLB** is not a good candidate for dividend investing.

With a **Dividend Yield** of **0.19**, **CLB** pays less dividend than the S&P500 average, which is at **2.21**.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.19% |

The dividend of **CLB** decreases each year by **-73.70%**.

Dividend Growth(5Y)-73.7%

Div Incr Years0

Div Non Decr Years2

DP5.09%

EPS Next 2Y16.17%

EPS Next 3Y17.29%

**CORE LABORATORIES INC**

NYSE:CLB (11/8/2024, 8:04:00 PM)

After market: 20.76 0 (0%)**20.76**

**-0.11 (-0.53%) **

Chartmill FA Rating

GICS SectorEnergy

GICS IndustryGroupEnergy

GICS IndustryEnergy Equipment & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap974.68M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.19% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 24.42 | ||

Fwd PE | 20.97 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)1.18

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 6.26% | ||

ROE | 16.32% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 11.27% | ||

PM (TTM) | 7.2% | ||

GM | 21.54% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.87

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.73 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.53 | ||

Quick Ratio | 1.72 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)3.66%

EPS 3Y4.92%

EPS 5Y

EPS Q2Q%

EPS Next Y20.71%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y